Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(3.25)
# 1,049
Out of 5,147 analysts
48
Total ratings
30%
Success rate
10.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $19.00 | +289.47% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $5.72 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $113.79 | -22.66% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $16.59 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $44.27 | - | 1 | Jul 17, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $8.67 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.34 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $29.69 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $16.78 | -22.47% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $4.10 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $60.14 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $101.27 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $30.23 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.14 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.30 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $191.82 | +52.23% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $496.83 | -25.53% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.20 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.63 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $19.00
Upside: +289.47%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $5.72
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $113.79
Upside: -22.66%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.59
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $44.27
Upside: -
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $8.67
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.34
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $29.69
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $16.78
Upside: -22.47%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.10
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $60.14
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $101.27
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.23
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.14
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.30
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $191.82
Upside: +52.23%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $496.83
Upside: -25.53%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.20
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.63
Upside: -